0001209191-18-010129.txt : 20180214
0001209191-18-010129.hdr.sgml : 20180214
20180214181613
ACCESSION NUMBER: 0001209191-18-010129
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180212
FILED AS OF DATE: 20180214
DATE AS OF CHANGE: 20180214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arbuckle Stuart A
CENTRAL INDEX KEY: 0001557290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 18614995
MAIL ADDRESS:
STREET 1: VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-02-12
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001557290
Arbuckle Stuart A
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP\Chief Commercial Officer
Common Stock
2018-02-12
4
S
0
875
150.78
D
61650
D
Common Stock
2018-02-12
4
S
0
800
152.27
D
60850
D
Common Stock
2018-02-12
4
S
0
3879
153.07
D
56971
D
Common Stock
2018-02-12
4
S
0
1270
153.80
D
55701
D
Common Stock
140
I
401(k)
Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1.
Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $150.78 (range $150.42 to $151.20).
Open market sales reported on this line occurred at a weighted average price of $152.27 (range $151.67 to $152.62).
Open market sales reported on this line occurred at a weighted average price of $153.07 (range $152.67 to $153.66).
Open market sales reported on this line occurred at a weighted average price of $153.80 (range $153.67 to $153.99).
/s/ Omar White, Attorney-in-Fact
2018-02-14